Sudachitin 是一种具有口服活性的化合物,可强效抑制小鼠 PDE1C 和人源 PDE4B(IC50 值分别为 5.0 μM 和 15.0 μM),通过上调骨骼肌中 Sirt1 和 PGC‑1α 的表达来调控能量代谢并促进线粒体生物发生,同时改善脂质代谢、葡萄糖耐量、胰岛素敏感性、能量消耗及脂肪酸 β- 氧化,并可激活 p38MAPK 信号通路,诱导 HSP27 磷酸化和半胱天冬酶依赖性的凋亡 (apoptosis),阻断 EGF 介导的角质形成细胞迁移与增殖,还能抑制巨噬细胞中 LPS 诱导的 TNF‑α、NO 和 iNOS 表达,具有强效抗炎活性,可用于研究代谢综合征、2 型糖尿病及银屑病。
产品编号: MS-T26283 CAS No.: 4281-28-1 分子式: C18H16O8 分子量: 360.31
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Sudachitin 是一种具有口服活性的化合物,可强效抑制小鼠 PDE1C 和人源 PDE4B(IC50 值分别为 5.0 μM 和 15.0 μM),通过上调骨骼肌中 Sirt1 和 PGC‑1α 的表达来调控能量代谢并促进线粒体生物发生,同时改善脂质代谢、葡萄糖耐量、胰岛素敏感性、能量消耗及脂肪酸 β- 氧化,并可激活 p38MAPK 信号通路,诱导 HSP27 磷酸化和半胱天冬酶依赖性的凋亡 (apoptosis),阻断 EGF 介导的角质形成细胞迁移与增殖,还能抑制巨噬细胞中 LPS 诱导的 TNF‑α、NO 和 iNOS 表达,具有强效抗炎活性,可用于研究代谢综合征、2 型糖尿病及银屑病。

生物实验数据

生物活性 Sudachitin is an orally active compound that potently inhibits mouse PDE1C and human PDE4B with IC50 values of 5.0 μM and 15.0 μM, respectively, upregulates Sirt1 and PGC‑1α expression in skeletal muscle to regulate energy metabolism and promote mitochondrial biogenesis, improves lipid metabolism, glucose tolerance, insulin sensitivity, energy expenditure, and fatty acid β-oxidation, activates the p38MAPK signaling pathway to induce HSP27 phosphorylation and caspase-dependent apoptosis (apoptosis), blocks EGF-mediated keratinocyte migration and proliferation, and inhibits LPS-induced TNF‑α, NO, and iNOS expression in macrophages with potent anti-inflammatory activity, making it useful for studying metabolic syndrome, type 2 diabetes, and psoriasis.
IC50 & Target

PDE1C

5 μM (IC50)

PDE4B

15 μM (IC50)

SIRT1

 

p38 MAPK

 

iNOS

 

体外研究
(In Vitro)

Sudachitin (30 μmol/L; 48 h) 可显著上调参与线粒体生物发生与葡萄糖转运的基因,并使原代小鼠骨骼肌肌细胞的线粒体密度增加 2.5 倍。
Sudachitin (30-100 μM; 24 h) 可诱导人角质形成细胞 HaCaT 发生 caspase 依赖性凋亡,这一点可被剪切型 Bid、caspase-3 和 PARP 的表达所证明。
Sudachitin (30-100 μM; 2-24 h) 可通过激活 MKK3/6-p38MAPK 通路诱导人角质形成细胞 HaCaT 凋亡,在 100 μM 浓度下 p38MAPK 的磷酸化可持续至 24 h。
Sudachitin (30 μM; 1 h pretreatment followed by EGF stimulation) 可抑制人角质形成细胞 HaCaT 中 EGF 诱导的 ERK1/2 活化,包括抑制 Raf-1 的磷酸化和 Elk-1 的转录活性。
Sudachitin (预处理 1 小时后暴露于 EGF 24 小时,浓度 30 μM) 可抑制 EGF 诱导的人角质形成细胞 HaCaT 的迁移与增殖。
Sudachitin (最高 30 μM;24 h) 不会降低小鼠巨噬细胞样 RAW264 细胞的存活率。
Sudachitin (10-30 μM; 12 h LPS stimulation) 可在 LPS 刺激前预处理时显著抑制小鼠巨噬细胞样 RAW264 细胞中 LPS 诱导的 TNF-α 产生。
Sudachitin (3-30 μM; 12 h LPS incubation) 可剂量依赖性抑制小鼠巨噬细胞样 RAW264 细胞中 LPS 诱导的 NO 生成,30 μM 浓度下可将硝酸盐水平降至接近基础水平。
Sudachitin (30 μM; 6 h LPS stimulation) 预处理可显著抑制 LPS 诱导的小鼠巨噬细胞样 RAW264 细胞中 TNF-α 和 iNOS 的 mRNA 表达。
Sudachitin (0.1-100 μM) 可抑制重组小鼠 PDE1C 的活性,其 IC50 为 5.0 μM (1 μM cGMP as substrate);同时可抑制重组人 PDE4B 的活性,其 IC50 为 15 μM (1 μM cAMP as substrate)。

Western Blot Analysis

Cell Line: human keratinocyte HaCaT cells
Concentration: 30 μM; 100 μM
Incubation Time: 24 h; 24 h (with Z-VAD-FMK (MS-L66221) pretreatment)
Result: Reduced full‑length Bid levels while elevating cleaved caspase‑3 levels in a concentration‑dependent manner.
Induced Bid cleavage, caspase‑3 activation, and PARP cleavage concentration‑dependently.
Markedly diminished sudachitin‑triggered PARP cleavage following Z‑VAD‑FMK pretreatment.

Western Blot Analysis

Cell Line: human keratinocyte HaCaT cells
Concentration: 30 μM; 100 μM; 30 μM (with Adezmapimod (MS-T90664) pretreatment)
Incubation Time: 4 h (concentration-dependence); 2 h, 4 h, 8 h, 24 h (time-dependence at 100 μM); 4 h, 24 h (with Adezmapimod pretreatment)
Result: Increased p38MAPK and MKK3/6 phosphorylation concentration- and time-dependently, while decreasing ERK1/2 phosphorylation concentration-dependently.
Adezmapimod pretreatment markedly reduced sudachitin-induced HSP27 phosphorylation and PARP cleavage.

Cell Migration Assay

Cell Line: human keratinocyte HaCaT cells
Concentration: 30 μM
Incubation Time: 1 h pretreatment, followed by 24 h incubation with EGF
Result: Reduced EGF-stimulated cell migration, with migration area decreased to 0.9-fold relative to EGF-only control over 24 h.

Cell Proliferation Assay

Cell Line: human keratinocyte HaCaT cells
Concentration: 10 μM
Incubation Time: 1 h pretreatment, followed by 24 h incubation with EGF
Result: Reduced EGF-stimulated BrdU incorporation to 0.9-fold, relative to EGF-only control over 24 h.

ELISA Assay

Cell Line: LPS-stimulated mouse macrophage-like RAW264 cells
Concentration: 10 μM, 30 μM (pretreated before LPS stimulation)
Incubation Time: 12 h (incubated with LPS)
Result: Significantly inhibited LPS-stimulated TNF-α production at both tested concentrations, with stronger inhibition observed at 30 μM than at 10 μM, and showed stronger inhibition than licochalcone A at 10 μM.

Real Time qPCR

Cell Line: LPS-stimulated mouse macrophage-like RAW264 cells
Concentration: 30 μM (pretreated before LPS stimulation)
Incubation Time: 6 h (incubated with LPS)
Result: Significantly suppressed LPS-stimulated iNOS expression by more than 50%.\nSignificantly reduced LPS-induced TNF-α expression.
体内研究
(In Vivo)

Sudachitin (每日口服 5 mg/kg,连续 12 周,于第 4 周进行间接测热) 可改善遗传性糖尿病 db/db 小鼠的空腹血糖、胰岛素敏感性与脂质代谢,同时提升能量消耗,且不影响其体重增长;在高脂饮食诱导的肥胖及代谢受损 C57BL/6J 小鼠中,相同处理可改善糖脂代谢、减少肥胖,并使能量消耗提升 45%。
Sudachitin (10 mg/kg;口服;每日一次;连续 7 天) 可增强 BALB/c 小鼠的抗原特异性细胞免疫和体液免疫应答,其中干扰素-γ 的产生量提升 1.8 倍,IgG1 滴度提升 2.1 倍,IgG2a 滴度提升 1.7 倍。

Animal Model: C57BL/6 J (male, 4 weeks of age, high-fat diet-induced obesity and metabolic syndrome)
Dosage: 5 mg/kg (12-week studies); 5 mg/kg (4-week indirect calorimetry studies)
Administration: p.o.; daily; 12 weeks; 4 weeks (indirect calorimetry)
Result: Reduced body weight gain, serum triglyceride and free fatty acid levels, fasting glucose and insulin, total body fat, subcutaneous fat, visceral fat, and adipocyte size in high-fat diet-fed mice.
Improved glucose tolerance and insulin sensitivity, and elevated plasma adiponectin levels.
Increased mRNA expression of GLUT4, UCP1, UCP3 in white adipose tissue and UCP2, PGC-1α, Sirt1 in skeletal muscle.
Enhanced skeletal muscle ATP content and citrate synthase activity, and raised oxygen consumption and total daily energy expenditure by 45% after 4 weeks of treatment.
Animal Model: db/db (4 weeks of age, genetic leptin receptor deficiency-induced type 2 diabetes)
Dosage: 5 mg/kg (12-week studies); 5 mg/kg (4-week indirect calorimetry studies)
Administration: p.o.; daily; 12 weeks; 4 weeks (indirect calorimetry)
Result: Did not affect body weight gain within 12 weeks. Reduced fasting blood glucose, serum triglyceride, and non‑esterified fatty acid levels.
Improved insulin sensitivity by decreasing the AUC of insulin tolerance test.
Enhanced oxygen consumption and total daily energy expenditure after 4 weeks of treatment.

化学信息

分子量 360.31
分子式 C18H16O8
CAS No. 4281-28-1

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础